4502 and TAK Related Headlines
Go Back- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
- Takeda (TAK) U.S. FDA Approves Subcutaneous Administration of ENTYVIO
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda (TAK) Announces U.S. FDA Approval of sNDA for ICLUSIG in Adult Patients with Newly Diagnosed Ph+ ALL
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
- FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
- Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
- Takeda Announces Chief Financial Officer Succession
- Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
- Takeda’s (TAK) GAMMAGARD LIQUID Approved by U.S. FDA for Adults with CIDP
- Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
- Takeda Named Global Top Employer for Seventh Consecutive Year
- U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
- Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
- Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
- Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic P
- Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
- Takeda (TAK) Announces Late-Breaking Data from Phase 2b Study of TAK-279
- Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology
- Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
- European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
- Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
- Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
- Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
- Takeda (TAK) Provides Update on EXKIVITY
- Takeda Provides Update on EXKIVITY® (mobocertinib)
- U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
- Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
- Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
- Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
- ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
- Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
- The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
- Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
- Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meet
- Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
- Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
- U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Takeda (TAK) Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio for Maintenance Therapy in Moderately to Severely Active UC
- Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colit
- Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
4502 and TAK Related Press Releases
Go Back- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
- FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
- Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
- Takeda Announces Chief Financial Officer Succession
- Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
- Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
- Takeda Named Global Top Employer for Seventh Consecutive Year
- U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
- Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
- Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
- Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic P
- Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
- Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology
- Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
- European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
- Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
- Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
- Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
- Takeda Provides Update on EXKIVITY® (mobocertinib)
- U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
- Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
- Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
- Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
- ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
- Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
- The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
- Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
- Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meet
- Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
- Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
- Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
- U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colit
- Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
4502 and TAK Related SEC Filings
Go Back- Form SD TAKEDA PHARMACEUTICAL
- Form 6-K TAKEDA PHARMACEUTICAL For: Apr 19
- Form 6-K TAKEDA PHARMACEUTICAL For: Apr 15
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 27
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 09
- Form SC 13G/A TAKEDA PHARMACEUTICAL Filed by: BlackRock Inc.
- Form SC 13G/A TAKEDA PHARMACEUTICAL Filed by: Sumitomo Mitsui Trust Holdings, Inc.
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 02
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 01
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 01
- Form 6-K TAKEDA PHARMACEUTICAL For: Jan 16
- Form 6-K TAKEDA PHARMACEUTICAL For: Dec 14
- Form 6-K TAKEDA PHARMACEUTICAL For: Nov 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Nov 13
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 18
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 18
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 02
- Form 6-K TAKEDA PHARMACEUTICAL For: Sep 28
- Form 6-K TAKEDA PHARMACEUTICAL For: Sep 11
- Form 6-K TAKEDA PHARMACEUTICAL For: Aug 01
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 27
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 12
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Wozniewski Thomas Otto Claus
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Sequeira Ramona
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Lugogo Mwana Pietrina
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Kim Julie So-Young
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Greco Gerard M
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 06
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 03
- Form S-8 TAKEDA PHARMACEUTICAL
- Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 28
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 28
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 23
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 23
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 01
- Form 6-K TAKEDA PHARMACEUTICAL For: May 30
- Form 6-K TAKEDA PHARMACEUTICAL For: May 30
- Form 6-K TAKEDA PHARMACEUTICAL For: May 30
- Form 6-K TAKEDA PHARMACEUTICAL For: May 30
- Form 6-K TAKEDA PHARMACEUTICAL For: May 17
- Form SD TAKEDA PHARMACEUTICAL
- Form 6-K TAKEDA PHARMACEUTICAL For: May 11
- Form 6-K TAKEDA PHARMACEUTICAL For: May 11
